相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。An autocrine signaling circuit in hepatic stellate cells underlies advanced fibrosis in nonalcoholic steatohepatitis
Shuang Wang et al.
SCIENCE TRANSLATIONAL MEDICINE (2023)
Complexity of ballooned hepatocyte feature recognition: Defining a training atlas for artificial intelligence-based imaging in NAFLD
Elizabeth M. Brunt et al.
JOURNAL OF HEPATOLOGY (2022)
Distinct contributions of metabolic dysfunction and genetic risk factors in the pathogenesis of non-alcoholic fatty liver disease
Panu K. Luukkonen et al.
JOURNAL OF HEPATOLOGY (2022)
Promises of microbiome-based therapies
Jasmohan S. Bajaj et al.
JOURNAL OF HEPATOLOGY (2022)
Metabolic and genetic contributions to NAFLD: Really distinct and homogeneous?
Elizabeth K. Speliotes et al.
JOURNAL OF HEPATOLOGY (2022)
Ethyl glucuronide in hair detects a high rate of harmful alcohol consumption in presumed non-alcoholic fatty liver disease
Katharina Staufer et al.
JOURNAL OF HEPATOLOGY (2022)
Microbiome-derived ethanol in nonalcoholic fatty liver disease
Abraham S. Meijnikman et al.
NATURE MEDICINE (2022)
Measuring the Alcohol in Alcohol-Associated Liver Disease: Choices and Challenges for Clinical Research
Jessica Mellinger et al.
HEPATOLOGY (2021)
Nonalcoholic Steatohepatitis: Current Thinking From the Division of Hepatology and Nutrition at the Food and Drug Administration
Frank A. Anania et al.
HEPATOLOGY (2021)
Aramchol in patients with nonalcoholic steatohepatitis: a randomized, double-blind, placebo-controlled phase 2b trial
V. Ratziu et al.
NATURE MEDICINE (2021)
ACC inhibitor alone or co-administered with a DGAT2 inhibitor in patients with non-alcoholic fatty liver disease: two parallel, placebo-controlled, randomized phase 2a trials
Roberto A. Calle et al.
NATURE MEDICINE (2021)
A Randomized, Controlled Trial of the Pan-PPAR Agonist Lanifibranor in NASH
Sven M. Francque et al.
NEW ENGLAND JOURNAL OF MEDICINE (2021)
Muscle fat content is strongly associated with NASH: a longitudinal study in patients with morbid obesity
Maxime Nachit et al.
JOURNAL OF HEPATOLOGY (2021)
TVB-2640 (FASN Inhibitor) for the Treatment of Nonalcoholic Steatohepatitis: FASCINATE-1, a Randomized, Placebo-Controlled Phase 2a Trial
Rohit Loomba et al.
GASTROENTEROLOGY (2021)
NGM282 Improves Liver Fibrosis and Histology in 12 Weeks in Patients With Nonalcoholic Steatohepatitis
Stephen A. Harrison et al.
HEPATOLOGY (2020)
Insulin sensitizer MSDC-0602K in non-alcoholic steatohepatitis: A randomized, double-blind, placebo-controlled phase IIb study
Stephen A. Harrison et al.
JOURNAL OF HEPATOLOGY (2020)
Inhibition of receptor-interacting protein kinase 1 improves experimental non-alcoholic fatty liver disease
Amine Majdi et al.
JOURNAL OF HEPATOLOGY (2020)
Effects of Belapectin, an Inhibitor of Galectin-3, in Patients With Nonalcoholic Steatohepatitis With Cirrhosis and Portal Hypertension
Naga Chalasani et al.
GASTROENTEROLOGY (2020)
Selonsertib for patients with bridging fibrosis or compensated cirrhosis due to NASH: Results from randomized phase III STELLAR trials
Stephen A. Harrison et al.
JOURNAL OF HEPATOLOGY (2020)
Causal relationships between NAFLD, T2D and obesity have implications for disease subphenotyping
Zhipeng Liu et al.
JOURNAL OF HEPATOLOGY (2020)
Lytic cell death in metabolic liver disease
Jeremie Gautheron et al.
JOURNAL OF HEPATOLOGY (2020)
Suboptimal reliability of liver biopsy evaluation has implications for randomized clinical trials
Beth A. Davison et al.
JOURNAL OF HEPATOLOGY (2020)
Emricasan (IDN-6556) Lowers Portal Pressure in Patients With Compensated Cirrhosis and Severe Portal Hypertension
Guadalupe Garcia-Tsao et al.
HEPATOLOGY (2019)
Laboratory mice born to wild mice have natural microbiota and model human immune responses
Stephan P. Rosshart et al.
SCIENCE (2019)
Fatty Liver Disease Caused by High-Alcohol-Producing Klebsiella pneumoniae (vol 30, pg 675, 2019)
Jing Yuan et al.
CELL METABOLISM (2019)
A randomized, placebo-controlled trial of emricasan in patients with NASH and F1-F3 fibrosis
Stephen A. Harrison et al.
JOURNAL OF HEPATOLOGY (2019)
Obeticholic acid for the treatment of non-alcoholic steatohepatitis: interim analysis from a multicentre, randomised, placebo-controlled phase 3 trial
Zobair M. Younossi et al.
LANCET (2019)
Association of Histologic Disease Activity With Progression of Nonalcoholic Fatty Liver Disease
David E. Kleiner et al.
JAMA NETWORK OPEN (2019)
Simtuzumab Is Ineffective for Patients With Bridging Fibrosis or Compensated Cirrhosis Caused by Nonalcoholic Steatohepatitis
Stephen A. Harrison et al.
GASTROENTEROLOGY (2018)
A randomized, placebo-controlled trial of cenicriviroc for treatment of nonalcoholic steatohepatitis with fibrosis
Scott L. Friedman et al.
HEPATOLOGY (2018)
GS-0976 Reduces Hepatic Steatosis and Fibrosis Markers in Patients With Nonalcoholic Fatty Liver Disease
Rohit Loomba et al.
GASTROENTEROLOGY (2018)
The FXR agonist PX20606 ameliorates portal hypertension by targeting vascular remodelling and sinusoidal dysfunction
Philipp Schwabl et al.
JOURNAL OF HEPATOLOGY (2017)
Wild Mouse Gut Microbiota Promotes Host Fitness and Improves Disease Resistance
Stephan P. Rosshart et al.
CELL (2017)
Development of hyperdynamic circulation and response to -blockers in compensated cirrhosis with portal hypertension
Candid Villanueva et al.
HEPATOLOGY (2016)
Long-Term Pioglitazone Treatment for Patients With Nonalcoholic Steatohepatitis and Prediabetes or Type 2 Diabetes Mellitus A Randomized Trial
Kenneth Cusi et al.
ANNALS OF INTERNAL MEDICINE (2016)
FXR agonist obeticholic acid reduces hepatic inflammation and fibrosis in a rat model of toxic cirrhosis
Len Verbeke et al.
SCIENTIFIC REPORTS (2016)
Significant Variations in Elastometry Measurements Made Within Short-term in Patients With Chronic Liver Diseases
Fabio Nascimbeni et al.
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY (2015)
Roles for Chemokines in Liver Disease
Fabio Marra et al.
GASTROENTEROLOGY (2014)
Increased De Novo Lipogenesis Is a Distinct Characteristic of Individuals With Nonalcoholic Fatty Liver Disease
Jennifer E. Lambert et al.
GASTROENTEROLOGY (2014)
Regression of cirrhosis during treatment with tenofovir disoproxil fumarate for chronic hepatitis B: a 5-year open-label follow-up study
Patrick Marcellin et al.
LANCET (2013)
Regression of Fibrosis and Reversal of Cirrhosis in Rats by Galectin Inhibitors in Thioacetamide-Induced Liver Disease
Peter G. Traber et al.
PLOS ONE (2013)
A morphometric and immunohistochemical study to assess the benefit of a sustained virological response in hepatitis C virus patients with cirrhosis
Roberta D'Ambrosio et al.
HEPATOLOGY (2012)
Inflammasome-mediated dysbiosis regulates progression of NAFLD and obesity
Jorge Henao-Mejia et al.
NATURE (2012)
Galectin-3 ablation protects mice from diet-induced NASH: A major scavenging role for galectin-3 in liver
Carla Iacobini et al.
JOURNAL OF HEPATOLOGY (2011)
Now There Are Many (Stages) Where Before There Was One: In Search of a Pathophysiological Classification of Cirrhosis
Guadalupe Garcia-Tsao et al.
HEPATOLOGY (2010)
Pioglitazone, Vitamin E, or Placebo for Nonalcoholic Steatohepatitis.
Arun J. Sanyal et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
The regulation of inflammation by galectin-3
Neil C. Henderson et al.
IMMUNOLOGICAL REVIEWS (2009)
Recombinant factor VIIa for variceal bleeding in patients with advanced cirrhosis: A randomized, controlled trial
Jaime Bosch et al.
HEPATOLOGY (2008)
Hepatic expression of galectin-3 and receptor for advanced glycation end products in patients with liver disease
M. Butscheid et al.
JOURNAL OF CLINICAL PATHOLOGY (2007)
Galectin-3 regulates myofibroblast activation and hepatic fibrosis
NC Henderson et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2006)
Sampling variability of liver biopsy in nonalcoholic fatty liver disease
V Ratziu et al.
GASTROENTEROLOGY (2005)
Design and validation of a histological scoring system for nonalcoholic fatty liver disease
DE Kleiner et al.
HEPATOLOGY (2005)
Recombinant factor VIIa for upper gastrointestinal bleeding in patients with cirrhosis: A randomized, double-blind trial
J Bosch et al.
GASTROENTEROLOGY (2004)
Hepatocyte apoptosis and Fas expression are prominent features of human nonalcoholic steatohepatitis
AE Feldstein et al.
GASTROENTEROLOGY (2003)
Stimulation of proliferation of rat hepatic stellate cells by galectin-1 and galectin-3 through different intracellular signaling pathways
N Maeda et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2003)
Calibration of p values for testing precise null hypotheses
T Sellke et al.
AMERICAN STATISTICIAN (2001)
分享论文
